Article Text

Download PDFPDF
Ticagrelor induced neutrophilic eccrine hidradenitis: a unique adverse effect of a new antiplatelet drug
  1. Anuradha Bishnoi1,2,
  2. Manju Daroach2,3,
  3. Divya Aggarwal4,
  4. Bishan Das Radotra4,
  5. Prashant Panda2,5,
  6. Davinder Parsad2
  1. 1 Post Graduate Institute of Medical Education and Research, Chandigarh, India
  2. 2 Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
  3. 3 Dermatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
  4. 4 Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
  5. 5 Cardiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
  1. Correspondence to Professor Davinder Parsad, Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India; parsad{at}me.com

Statistics from Altmetric.com

Dear Editor,

Ticagrelor is a recently introduced antiplatelet drug that has shown superiority over clopidogrel in reducing overall mortality in acute coronary syndrome (ACS). The drug is an ADP P2Y12 receptor inverse agonist.1 We report here a patient who developed neutrophilic eccrine hidradenitis (NEH) 3 days after initiating ticagrelor.

A 66-year-old farmer was hospitalised after he was diagnosed with an ST elevation ACS. He was a known smoker, and had been receiving aspirin for the past 2 years. During his stay in hospital, he was administered loading doses of aspirin and ticagrelor, before stenting was performed in the left anterior descending branch of the left coronary artery. He was subsequently discharged on ticagrelor 90 mg twice daily (orally). The rest of the medications were continued. Following hospital discharge, after 3 days he developed multiple painful erythematous papulonodules on both palms.

When he presented to us he had multiple dusky, erythematous to violaceous, tender papulonodules and plaques symmetrically …

View Full Text

Footnotes

  • Contributors AB and DP had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: BDR, DP, PP and MD. Acquisition, analysis and interpretation of the data: AB, MD, DA and BDR. Drafting of the manuscript: AB, MD and DA. Critical revision of the manuscript for important intellectual content: DP and BDR.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.